Short answer
Bicara Therapeutics Inc. (BCAX) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release announces Bicara Therapeutics’ financial results for the quarter ended September 30, 2026.
Bicara Therapeutics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release announces Bicara Therapeutics’ financial results for the quarter ended September 30, 2026
- Business updates accompany the quarterly results, with substantive details in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- FORTIFI-HN01 achieved substantial enrollment, supporting topline interim results in mid-2027 for first-line HPV-negative HNSCC
- Cash, equivalents and marketable securities reached $442.3 million, funding operations into the first half of 2029 under current plans
- Third-quarter R&D expense rose to $56.5 million from $33.0 million, reflecting pivotal and alternate-dosing trial investment
- Net loss widened to $71.2 million from $36.3 million, with G&A increasing to $19.2 million for commercialization preparation
- FORTIFI-FLEX is testing 1,500mg weekly loading followed by 2,250mg every three weeks, with data expected by potential U.S. approval
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Bicara Therapeutics Inc. 8-K filings
Get the next BCAX 8-K as it lands
Follow BCAX for push alerts, or ask the research agent what this filing means.